Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

NCT02343120 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancies

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene